FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275199929> ?p ?o ?g. }

• W2275199929 endingPage "v1" @default.
• W2275199929 startingPage "v1.5" @default.
• W2275199929 abstract "LB-05. PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL W. Wick1, AA. Brandes2, T. Gorlia3, M. Bendszus1, F. Sahm1, W. Taal4, M. Taphoorn5, J. Domont6, A. Idbaih7, M. Campone8, P.M. Clement9, R. Stupp10, M. Fabbro11, F. Dubois12, C. Bais13, D. Musmeci3, M. Platten1, M. Weller10, V. Golfinopoulos3, and M. van den Bent4; University Medical Center & German Cancer Research Center, Heidelberg, Germany; Medical Oncology Department, AUSL-Bologna-IRCCS Scienze Neurologiche, Bologna, Italia; EORTC Headquarters, Brussels, Belgium; Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; Medical Center Haaglanden, The Hague, The Netherlands The Netherlands; Institut Gustave Roussy, Villejuif, France; AP-HP, Hopital Universitaire La Pitie Salperiere and Sorbonne Universites, UPMC Univ Paris 06, Paris, France; Institut de Cancerologie de l’Ouest (ICO) Centre Rene Gauducheau, Saint-Herblain, France; U.Z. Leuven KU Leuven, Belgium; Zurich University Medical Center, Zurich, Switzerland; Institut regional du Cancer Montpellier, Montpellier, France; CHRU de Lille, Lille, France; Genentech Inc., South San Francisco, California, USA BACKGROUND: Phase II data from the BELOB trial indicated that the combination of bevacizumab and lomustine might produce an overall survival (OS) benefit compared with either monotherapy for patients with first progression of a glioblastoma. The primary objective of the phase III part of EORTC 26101 is to investigate whether the addition of bevacizumab to lomustine improves overall OS in patients with first progression of a glioblastoma compared to treatment with lomustine alone. METHODS: Patients with progressive disease after standard chemo-radiotherapy with temozolomide at least 3 months off the concomitant part were randomized 2:1 between lomustine 90 mg/m (cap. 160 mg) mg every six weeks plus 10 mg/kg bevacizumab every two weeks and lomustine single agent 110 mg/m (cap. 200 mg) every six weeks followed by best investigators choice at further progression. In the absence of hematological toxicity . grade 1 during the first cycle in the combination arms, the dose of lomustine could be escalated to 110 mg/m (cap 200 mg) in the second cycle. Neuroimaging according to a standard protocol was assessed locally and centrally. RESULTS: A total of 437 (288 and 149, respectively) patients were included. Median number of treatment cycles was 1 in the lomustine arm and 3 in the combination arm. With 329 OS events (75.3%) OS was not superior in the combination therapy arm (hazard ratio (HR) 0.95 (confidence interval (CI) 0.74, 1.21), p 1⁄4 0.650, analyses stratified by EORTC online randomization system), whereas locally assessed progression-free survival (PFS) was longer with the addition of bevacizumab to lomustine (HR 0.49 (CI 0.39, 0.61). Median efficacy outcomes were: OS 9.1 (8.1, 10.1) versus 8.6 (7.6, 10.4) months and PFS 4.2 (3.7, 4.3) versus 1.5 (1.5, 2.5) months in the combination arm versus the lomustine arm respectively. Toxicity was in the expected range with more events in the combination arm being also longer on treatment. Crossover to bevacizumab occurred in 35.5% of patients in the control arm; whereas 19% of patients in the combination arm continued bevacizumab at progression. CONCLUSIONS: Bevacizumab treatment in patients with progressive glioblastoma despite prolonged PFS does not confer a survival advantage. The future challenge is to identify those patients deriving benefit from that treatment. Neuro-Oncology 17:v1–v1, 2015. doi:10.1093/neuonc/nov306 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015." @default.
• W2275199929 created "2016-06-24" @default.
• W2275199929 creator A5001037498 @default.
• W2275199929 creator A5003817127 @default.
• W2275199929 creator A5015090277 @default.
• W2275199929 creator A5017177249 @default.
• W2275199929 creator A5019876508 @default.
• W2275199929 creator A5022934821 @default.
• W2275199929 creator A5026126995 @default.
• W2275199929 creator A5027716902 @default.
• W2275199929 creator A5032455600 @default.
• W2275199929 creator A5038129366 @default.
• W2275199929 creator A5049799682 @default.
• W2275199929 creator A5053052330 @default.
• W2275199929 creator A5056837393 @default.
• W2275199929 creator A5064778456 @default.
• W2275199929 creator A5071553983 @default.
• W2275199929 creator A5074755682 @default.
• W2275199929 creator A5080482957 @default.
• W2275199929 creator A5080503349 @default.
• W2275199929 creator A5086083902 @default.
• W2275199929 creator A5086283695 @default.
• W2275199929 date "2015-11-01" @default.
• W2275199929 modified "2023-10-03" @default.
• W2275199929 title "LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL" @default.
• W2275199929 doi "https://doi.org/10.1093/neuonc/nov306" @default.
• W2275199929 hasPublicationYear "2015" @default.
• W2275199929 type Work @default.
• W2275199929 sameAs 2275199929 @default.
• W2275199929 citedByCount "54" @default.
• W2275199929 countsByYear W22751999292015 @default.
• W2275199929 countsByYear W22751999292016 @default.
• W2275199929 countsByYear W22751999292017 @default.
• W2275199929 countsByYear W22751999292018 @default.
• W2275199929 countsByYear W22751999292019 @default.
• W2275199929 countsByYear W22751999292021 @default.
• W2275199929 countsByYear W22751999292022 @default.
• W2275199929 crossrefType "journal-article" @default.
• W2275199929 hasAuthorship W2275199929A5001037498 @default.
• W2275199929 hasAuthorship W2275199929A5003817127 @default.
• W2275199929 hasAuthorship W2275199929A5015090277 @default.
• W2275199929 hasAuthorship W2275199929A5017177249 @default.
• W2275199929 hasAuthorship W2275199929A5019876508 @default.
• W2275199929 hasAuthorship W2275199929A5022934821 @default.
• W2275199929 hasAuthorship W2275199929A5026126995 @default.
• W2275199929 hasAuthorship W2275199929A5027716902 @default.
• W2275199929 hasAuthorship W2275199929A5032455600 @default.
• W2275199929 hasAuthorship W2275199929A5038129366 @default.
• W2275199929 hasAuthorship W2275199929A5049799682 @default.
• W2275199929 hasAuthorship W2275199929A5053052330 @default.
• W2275199929 hasAuthorship W2275199929A5056837393 @default.
• W2275199929 hasAuthorship W2275199929A5064778456 @default.
• W2275199929 hasAuthorship W2275199929A5071553983 @default.
• W2275199929 hasAuthorship W2275199929A5074755682 @default.
• W2275199929 hasAuthorship W2275199929A5080482957 @default.
• W2275199929 hasAuthorship W2275199929A5080503349 @default.
• W2275199929 hasAuthorship W2275199929A5086083902 @default.
• W2275199929 hasAuthorship W2275199929A5086283695 @default.
• W2275199929 hasBestOaLocation W22751999291 @default.
• W2275199929 hasConcept C126322002 @default.
• W2275199929 hasConcept C143998085 @default.
• W2275199929 hasConcept C2776194525 @default.
• W2275199929 hasConcept C2776694085 @default.
• W2275199929 hasConcept C2776755627 @default.
• W2275199929 hasConcept C2777802072 @default.
• W2275199929 hasConcept C2779429289 @default.
• W2275199929 hasConcept C2779434656 @default.
• W2275199929 hasConcept C502942594 @default.
• W2275199929 hasConcept C71924100 @default.
• W2275199929 hasConceptScore W2275199929C126322002 @default.
• W2275199929 hasConceptScore W2275199929C143998085 @default.
• W2275199929 hasConceptScore W2275199929C2776194525 @default.
• W2275199929 hasConceptScore W2275199929C2776694085 @default.
• W2275199929 hasConceptScore W2275199929C2776755627 @default.
• W2275199929 hasConceptScore W2275199929C2777802072 @default.
• W2275199929 hasConceptScore W2275199929C2779429289 @default.
• W2275199929 hasConceptScore W2275199929C2779434656 @default.
• W2275199929 hasConceptScore W2275199929C502942594 @default.
• W2275199929 hasConceptScore W2275199929C71924100 @default.
• W2275199929 hasIssue "suppl 5" @default.
• W2275199929 hasLocation W22751999291 @default.
• W2275199929 hasLocation W22751999292 @default.
• W2275199929 hasOpenAccess W2275199929 @default.
• W2275199929 hasPrimaryLocation W22751999291 @default.
• W2275199929 hasRelatedWork W2003869210 @default.
• W2275199929 hasRelatedWork W2275199929 @default.
• W2275199929 hasRelatedWork W2512596242 @default.
• W2275199929 hasRelatedWork W2586751687 @default.
• W2275199929 hasRelatedWork W2588571677 @default.
• W2275199929 hasRelatedWork W2767479129 @default.
• W2275199929 hasRelatedWork W2767512538 @default.
• W2275199929 hasRelatedWork W2768388636 @default.
• W2275199929 hasRelatedWork W2942024685 @default.
• W2275199929 hasRelatedWork W2943268909 @default.
• W2275199929 hasVolume "17" @default.
• W2275199929 isParatext "false" @default.
• W2275199929 isRetracted "false" @default.
• W2275199929 magId "2275199929" @default.

• next